Previous 10 | Next 10 |
Gainers: [[HTOOW]] +18.7%. [[SIF]] +16.4%. [[GBS]] +11.9%. [[ODT]] +10.9%. [[LAZRW]] +10.2%.Losers: [[ALT]] -10.5%. [[BFIIW]] -5.8%. [[BLU]] -4.2%. [[SCPL]] -4.0%. [[CATB]] -3.4%. For further details see: HTOOW, SIF, ALT and CATB among after-hours movers
NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced the appointment of Dr. Jeffrey Vacirca to its ...
In a presentation at the 2020 San Antonio Breast Cancer Symposium, Odonate Therapeutics (ODT) announced positive Phase 3 clinical trial data for tesetaxel, its therapeutic candidate for metastatic breast cancer. The multinational, multicenter, randomized, Phase 3 study, conducted in North Ame...
Odonate Therapeutics ([[ODT]] -0.8%) announces positive results from a multinational, multicenter, randomized CONTESSA, Phase 3 trial evaluating lead candidate tesetaxel in metastatic breast cancer ((MBC)) patients.The study met the primary endpoint of improved Progre...
CONTESSA Achieved Primary Endpoint – Tesetaxel Plus a Reduced Dose of Capecitabine Significantly Improved Progression-free Survival (PFS) Versus the Approved Dose of Capecitabine Alone (Hazard Ratio=0.716; p=0.003) Median PFS Was 9.8 Months for Tesetaxel Plus a Reduced ...
vTv Therapeutics VTVT +128% as MacAndrews & Forbes buys 625K shares.Sonoma Pharmaceuticals SNOA +122% on Crown Laboratories partnership.FAT Brands FAT +60% on plan to merge with controlling shareholder Fog Cutter Capital.Lexicon Pharmaceuticals LXRX +38%...
Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced the initiation of Cohort 3 of CONTESSA TRIO, which will evaluate tesetaxel monothe...
Event will follow presentation of results of CONTESSA, a Phase 3 study of tesetaxel in patients with metastatic breast cancer, at the 2020 San Antonio Breast Cancer Symposium (SABCS) Featured speakers will include Lee Schwartzberg, M.D., FACP, Chief Medical Director, West Canc...
Odonate Therapeutics (ODT): Q3 GAAP EPS of -$0.93 in-line.Cash of $188.3MPress Release For further details see: Odonate Therapeutics EPS in-line
Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and nine months ended September 30, 2020. As o...
News, Short Squeeze, Breakout and More Instantly...
Odonate Therapeutics Inc. Company Name:
ODT Stock Symbol:
NASDAQ Market:
Odonate Therapeutics Inc. Website:
Odonate Therapeutics, Inc. (NASDAQ: ODT) today announced that on January 6, 2022 it received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) notifying Odonate that Nasdaq believes that Odonate is a "public shell" pursuant to Listing Rule 5101, and that the c...
ODONATE INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Odonate Therapeutics, Inc. - ODT ODONATE INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, L...
Odonate Therapeutics, Inc. (NASDAQ: ODT) today announced that it will commence a share repurchase plan for up to 20 million shares in order to return capital to stockholders. This action is in connection with the Company’s previously announced decision to discontinue the deve...